Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Price Target of $32.25

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $32.25.

Several brokerages have recently issued reports on DTIL. Wall Street Zen downgraded Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday, August 5th.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $5.77 on Monday. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $7.09 and a two-hundred day moving average price of $7.19. The firm has a market capitalization of $159.25 million, a price-to-earnings ratio of -2.06 and a beta of 1.27. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. Sell-side analysts expect that Precision BioSciences will post -3.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC acquired a new position in shares of Precision BioSciences during the first quarter valued at approximately $3,289,000. Octagon Capital Advisors LP raised its holdings in Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after purchasing an additional 318,737 shares in the last quarter. Corient Private Wealth LP raised its stake in shares of Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock worth $1,926,000 after buying an additional 101,206 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Precision BioSciences by 212.7% in the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after buying an additional 93,258 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Precision BioSciences in the second quarter valued at $467,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing therapies for serious diseases. The company’s work is based primarily on its proprietary ARCUS platform, which uses engineered nucleases designed to make precise changes to DNA inside the body.

Precision BioSciences is focused on in vivo gene editing programs addressing conditions including chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency. Its development efforts are intended to remove, insert or repair genetic material and potentially provide durable treatments after a single administration.

Founded in 2006 and headquartered in Durham, North Carolina, the company has also pursued cell therapy programs and strategic collaborations to apply its gene-editing technology to additional therapeutic areas.